BRIEF published on 12/09/2024 at 14:10, 12 days 1 hour ago Theralase élargit ses sites d'études cliniques pour le traitement du cancer de la vessie aux États-Unis Recherche Sur Le Cancer Expansion De La Théralase Traitement Du Cancer De La Vessie Sites D'études Cliniques Activation De Ruvidar
BRIEF published on 12/09/2024 at 14:10, 12 days 1 hour ago Theralase Expands Clinical Study Sites for Bladder Cancer Treatment in the U.S. Cancer Research Bladder Cancer Treatment Theralase Expansion Clinical Study Sites Ruvidar Activation
PRESS RELEASE published on 12/09/2024 at 14:05, 12 days 1 hour ago Theralase(R) Launches Three New Clinical Study Sites in USA Theralase® launches new US Clinical Study Sites for bladder cancer treatment. Principal Investigators announced. Positive clinical data presented Clinical Data Theralase® Bladder Cancer US Clinical Study Sites
BRIEF published on 12/05/2024 at 13:05, 16 days 2 hours ago Theralase Technologies étend son étude sur le cancer de la vessie au Canada Étude Clinique Cancer De La Vessie Ruvidar Technologies Théralase Expansion Au Canada
BRIEF published on 12/05/2024 at 13:05, 16 days 2 hours ago Theralase Technologies Expands Bladder Cancer Study in Canada Canada Expansion Clinical Study Bladder Cancer Ruvidar Theralase Technologies
PRESS RELEASE published on 12/05/2024 at 13:00, 16 days 2 hours ago Theralase(R) Launches New Clinical Study Site in Canada St. Joseph's Healthcare Hamilton joins Theralase®'s clinical investigation for bladder cancer treatment. Theralase® develops light-activated Ruvidar™ drug for BCG-Unresponsive NMIBC CIS patients Theralase® Bladder Cancer BCG-Unresponsive NMIBC CIS RuvidarTM Clinical Study Site
BRIEF published on 11/27/2024 at 23:10, 23 days 16 hours ago Theralase publie son aperçu financier du troisième trimestre 2024 Placements Privés Dépenses De Recherche Et Développement Aperçu Financier De Theralase Chiffre D'affaires Et Marges Résultats De L'étude II
BRIEF published on 11/27/2024 at 23:10, 23 days 16 hours ago Theralase Releases 3Q2024 Financial Overview Private Placements R&D Expenses Theralase Financial Overview Revenue And Margins Study II Results
PRESS RELEASE published on 11/27/2024 at 23:05, 23 days 16 hours ago Theralase(R) Release’s 3Q2024 Financial Statements Theralase® Technologies Inc. releases unaudited financial statements for the nine-month period ended September 30, 2024, showcasing key financial and operational results. Conference call scheduled for December 4th Conference Call Financial Statements Operational Results Theralase® Technologies Inc. Study II
BRIEF published on 11/15/2024 at 13:05, 1 month 6 days ago Theralase Technologies conclut un placement privé de 666 400 $CAN Placement Privé Cancer De La Vessie Technologies Théralase Mandats Stade Clinique
Published on 12/21/2024 at 01:30, 14 hours 2 minutes ago Quantum Biopharma Announces Closing of Second Tranche
Published on 12/21/2024 at 01:30, 14 hours 2 minutes ago iMetal Resources Closes First Tranche of Previously Announced Non-Brokered Private Placement
Published on 12/21/2024 at 00:05, 15 hours 27 minutes ago Chloeta Awarded GSA OASIS+ IDIQ Contract for Intelligence, Federal Civilian and Defense Support Services
Published on 12/20/2024 at 23:30, 16 hours 2 minutes ago Boron One Announces Extension to Early Warrant Exercise Incentive Program
Published on 12/21/2024 at 00:51, 14 hours 41 minutes ago Acquisition of PSI Transcom GmbH by CHAPTERS platform Altamount Software GmbH
Published on 12/21/2024 at 00:45, 14 hours 47 minutes ago EQS-Adhoc: PSI sells the Mobility business unit
Published on 12/20/2024 at 19:10, 20 hours 22 minutes ago Funding Circle Plc: POS-Transaction in Own Shares
Published on 12/20/2024 at 18:56, 20 hours 36 minutes ago CPI PROPERTY GROUP – Progress on Key Initiatives
Published on 12/20/2024 at 18:00, 21 hours 32 minutes ago ARYZTA AG Announces New Board Technology Committee
Published on 12/21/2024 at 12:17, 3 hours 15 minutes ago AXA annonce la signature d’un accord relatif à la vente d'AXA Investment Managers à BNP Paribas
Published on 12/21/2024 at 12:17, 3 hours 15 minutes ago AXA announces the signing of a share purchase agreement with BNP Paribas relating to the sale of AXA IM
Published on 12/20/2024 at 18:00, 21 hours 32 minutes ago Kapitaalverhoging door uitoefening van inschrijvingsrechten
Published on 12/20/2024 at 18:00, 21 hours 32 minutes ago Capital increase through exercise of subscription rights
Published on 12/20/2024 at 17:55, 21 hours 37 minutes ago Déclaration des transactions sur actions propres réalisées du 16/12/2024 au 20/12/2024
